# NCT03914625 (NCT03914625)

> A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03914625
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: National Cancer Institute (NCI)
- Conditions: B Acute Lymphoblastic Leukemia; B Lymphoblastic Lymphoma; Down Syndrome
- Interventions: Asparaginase Erwinia chrysanthemi; Blinatumomab; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin Hydrochloride; Leucovorin Calcium; Mercaptopurine; Mercaptopurine Oral Suspension; Methotrexate; Pegaspargase; Prednisolone; Prednisone; Radiation Therapy; Radiation Therapy; Thioguanine; Vincristine Sulfate
- Enrollment: 6720
- Primary outcome: Disease free survival (DFS) in randomization eligible patients with higher risk features (SR-High) or standard risk average (SR-Avg) B-ALL patients based on randomization with addition of blinatumomab
- Primary outcome: DFS in boys in the SR-favorable subset of SR B-ALL with or without Down syndrome (DS)

## Commentary we found

- Podcasts: 6
- X threads: 3
- YouTube: 2

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct03914625

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03914625", "email": "<work email>"}; the inbox owner confirms by the emailed link.